Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Forecasts Single-Digit Revenue Increase in 2009

NEW YORK (GenomeWeb News) — Caliper Life Sciences said today it expects its fourth-quarter 2008 revenues to be $36.5 million, near the upper end of its previous guidance for the quarter of $34 million to $37 million, but 9 percent lower than revenues for the year-ago quarter of $40.3 million.

The company said that it expects to post $133.9 million in full-year 2008 revenue, approximately 5 percent lower than its full-year 2007 revenues of $140.7 million.

During the fourth quarter, Caliper sold its Pharmaceutical Development & Quality and AutoTrace product lines for a total of around $21 million. The company said today that 2008 pro forma revenue, which reflects the divestiture of those product lines, is expected to be approximately $34.6 million for the fourth quarter and $122.8 million for the full year.

For 2009, Caliper currently expects total revenue to increase around 4 percent to 7 percent over 2008 pro forma revenue, with the growth primarily occurring in the second half of the year. In its preliminary revenue statement, the company cited "currency headwinds" as a key factor for its estimates.

The company noted that these financial results are preliminary and are subject to change.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.